GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In March 2022, Johnson & Johnson Vision Care, Inc., a global leader in eye health and part of the Johnson & Johnson Medical Device Company, announced that the U.S. FDA has approved ACUVUE Theravision with Ketotifen (etafilcon). Ketotifen-eluting contact lenses. Each lens contains 19 mcg of ketotifen. Ketotifen is a well-known antihistamine. ACUVUE Theravision with Ketotifen is the first in a completely new category of contact lenses, offering a fresh wearing experience for contact lens wearers with allergic eye itch.
• In January 2022, Glenmark Pharmaceuticals Ltd., an innovation-driven, global, integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A., has signed an exclusive licensing agreement with Lotus International Pte. Ltd., a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Lotus), to commercialize its innovative nasal spray Ryaltris in Singapore, Hong Kong, and Vietnam.
• In May 2021, Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, announced the launch of Ryaltris-AZ Nasal Spray in India for the treatment of mild to severe allergic rhinitis. Glenmark, a respiratory market leader, was the first to develop a branded generic version at an affordable price for the treatment of allergic rhinitis in India. This will give patients with a considerably more convenient and cost-effective treatment alternative across the country.
• In June 2020, Cadila Pharmaceuticals Limited, an India-based pharmaceutical company, recently announced the launch of Bilastine syrup (30 mL) and Bilastine tablets (20mg). Bilastine, an antihistamine medication, is suggested for the treatment of allergic rhinitis.